Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
“More importantly, a low concentration of RSV was synergistic with a low dose of the proteasome inhibitor carfilzomib (CFZ) to induce apoptosis in myeloma cells…
Bortezomib (velcade), Carfilzomib (kyprolis) and Ixazomib (ninlaro) are all proteasome inhibitors. All three chemotherapy drugs are multiple myeloma chemotherapy regimens approved by the FDA.
The challenge for multiple myeloma survivors however, is that each proteasome inhibitor will stop working eventually. MDR aka multi-drug resistance is a fact for all multiple myeloma chemotherapy regimens.
If you are a MM patient or survivor who has undergone several multiple myeloma chemotherapy regimens already and is wondering about your next therapy steps, consider integrative therapies- combinations of conventional and non-conventional proteasome inhibitors that integrate or enhance each other.
While the solution, in my experience anyway, is evidence-based, it is not FDA approved. In other words, the studies linked below explain that
all integrate with and enhance conventional MM protease inhibitors Bortezomib and Carfilzomib, but they are not FDA approved. This is why “non-conventional therapies” are called “non-conventional.” Because conventional oncology doesn’t study them and the FDA won’t approve them.
I can’t help but wonder if these non-conventional therapies also integrate with Ixazomib (ninlaro).
When I was first diagnosed with MM, I was all about conventional therapies including surgery, radiation and chemotherapy. Lots of radiation and chemotherapy. Lots of short, long-term and late stage side effects.
Until my oncologist told me that “we can do nothing more for you.” Dr. Rassiga told me that in my last appointment with her at the end of September of 1997. I was at the Burzynski Clinic in Houston, Texas two months later learning about “non-conventional therapies.”
I achieved complete remission 17 months later. Now I’m all about integrating conventional with non-conventional therapies for multiple myeloma patients and survivors.
My point is that conventional oncology cannot cure multiple myeloma. The average patient survival of 5-7 years will pass by quickly. The years will pass quickly because you may be consumed by managing your short, long-term and late stage side effects.
Consider evidence-based conventional as well as non-conventional MM therapies. Add a healthy dose of complementary therapies such as nutrition, exercise and nutritional supplementation.
Scroll down the page, ask a question or make a comment. I will reply to you ASAP.
Thank you and hang in there,
“Proteasome inhibitors are drugs that block the action of proteasomes, cellular complexes that break down proteins. They are being studied in the treatment of cancer; and three are approved for use in treating multiple myeloma.”
“The n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been shown to enhance the effect of chemotherapeutic drugs in clinical studies in cancer patients and to induce apoptotic tumor cell death in vitro.
Until now, EPA and DHA have never been investigated in multiple myeloma (MM). Human myeloma cells (L363, OPM-1, OPM-2 and U266) and normal peripheral blood mononuclear cells were exposed to EPA and DHA, and effects on mitochondrial function and apoptosis, caspase-3 activation, gene expression and drug toxicity were measured.
Exposure to EPA and DHA induced apoptosis and increased sensitivity to bortezomib in MM cells…
Our study suggests that EPA and DHA induce selective cytotoxic effects in MM and increase sensitivity to bortezomib and calls for further exploration into a potential application of these n-3 polyunsaturated fatty acids in the therapy of MM…”
“The proteasome plays a vital role in the degradation of proteins involved in several pathways including the cell cycle, cellular proliferation and apoptosis and is a validated target in cancer treatment. Bortezomib (Velcade®, PS-341) is the first US FDA approved proteasome inhibitor anticancer drug used in the treatment of refractory multiple myeloma.
In spite of its improved efficacy compared to alternative therapies, about 60% of patients do not respond to bortezomib due to the emergence of resistance…
We hypothesized that novel small molecules could enhance the proteasome-inhibitory and anticancer activities of bortezomib in resistant multiple myeloma cells in vitro and in vivo…”
“The proteasome inhibitor is a target therapy for multiple myeloma (MM) patients, which has increased the overall survival rate of multiple myeloma in clinic. However, relapse and toxicity are major challenges for almost all MM patients.
Thus, there is an urgent need for an effective and less toxic combination therapy. Here, we demonstrated that a natural compound, resveratrol (RSV) displayed anti-proliferative activity in a dose- and time-dependent manner in a panel of MM cell lines.
More importantly, a low concentration of RSV was synergistic with a low dose of the proteasome inhibitor carfilzomib (CFZ) to induce apoptosis in myeloma cells…
Together, these findings suggest that induction of multiple stress responses after RSV/CFZ combination is a major mechanism to synergistically inhibit MM cell growth and reduce the toxicity of CFZ in MM cells.
This study also provides an important rationale for the clinic to consider an autophagy inhibitor for the combination therapy in MM patients…”
“Our results show that TQ inhibited the proliferation of MM cells irrespective of their sensitivity to doxorubicin, melphalan or bortezomib.
TQ also potentiated the apoptotic effects of bortezomib in various MM cell lines through the activation of caspase-3, resulting in the cleavage of PARP…”
” Here we show that HNK significantly induces cytotoxicity in human multiple myeloma (MM) cell lines and tumor cells from patients with relapsed refractory MM...
Furthermore, HNK enhances MM cell cytotoxicity and apoptosis induced by bortezomib…”